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ABSTRACT 
Aims: To explore barriers and facilitators to using and 
adhering to Truvada, among HIV-negative, post-
incarcerated, African American men who have sex with 
men (MSM).  Background: African American MSM 
represent only 2% of the U.S. population, yet account for 
73% of new HIV infections among African American men. 
Truvada was FDA approved in 2012 for chemoprophylaxis 
in HIV-negative persons at high HIV risk. According to 
CDC guidelines, Truvada is most efficacious when used 
daily in addition to consistent condom use from the 
beginning to end of sex, and with 2-3 month medical checks 
and counseling. Methods: In this qualitative ethnographic 
study we used convenience and snowball sampling. 
Participants were recruited from Men’s Central Jail in Los 
Angeles in collaboration with the Center for Health Justice. 
Data were gathered using semi-structured questions in one 
and one half hour, audio-recorded, focus group sessions. 
Analysis: Transcripts were analyzed using AtlasTi 
qualitative software. Findings: 1. HIV-related stigma 
continues in African American communities 2. Post-
incarcerated HIV-negative African American MSM may 
not consistently use or adhere to Truvada 3. Use of 
Truvada may mean that the user is HIV positive or gay, 
and 4. African American MSM may not use condoms with 
Truvada. 5. Truvada should be given to men who are 
incarcerated. 
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Introduction 
The HIV/AIDS public health crisis in African 
American U.S. communities remains perplexing. African 
American men account for 70% of all new HIV infections 
within their race/ethnicity1 (CDC, 2012). However, there is 
cause for even more pressing concern among African 
American men who have sex with men (MSM). African 
American MSM represent only 2% of the U.S. population, 
yet they account for 73% of new HIV infections among 
African American men.1  
A unique critical context in which HIV 
acquisition 
and transmission occurs is that of social injustice leading to 
historically higher rates of African American male 
incarceration and recidivism. It is noteworthy that some men 
do have sex with men while incarcerated, and that there is a 
high correlation between incarceration and high-risk sex 
behaviors.6 Prison HIV rates in 2002 were 3.5 times that of 
the U.S. general population and HIV risk is even higher 
among African American incarcerated men.7 CDC (2015)8 
reports indicate that jailed African American men are 5 
times more likely than White counterparts to be diagnosed 
with HIV. Sexual networking patterns of African Americans 
noted earlier may transfer to incarceration settings, thus 
increasing HIV risk. In addition, activities such as tattooing 
without clean needles and injection drug use that can occur 
during incarceration increase HIV risk.9  
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Further complicating the HIV public health 
problem among African American MSM is perceived HIV 
stigma and homophobia in the health care system that 
perpetuate secrecy and diminish health-seeking behaviors 
while increasing risk.10 Moreover, racism and sexual 
discrimination within the health care system can lead to less 
access to health care, and to Truvada. This may be so 
particularly for those holding a double minority status as 
being both African American and being a man who has sex 
with men. The problem is that Truvada providers may 
hesitate to prescribe this medication for such individuals, 
while the provision of Truvada is heavily reliant upon 
prescriber discretion. This is evident in reports that 
providers may be less likely to provide Truvada to Black 
MSM than White MSM.10 This racism and discrimination 
may be based on assumptions by prescribers that Black men 
would be more likely than White men to increase their 
participation in unprotected sex if prescribed Truvada11 
However, some reports indicate that high HIV rates in Black 
communities may not be attributable to Black MSM 
participating in more frequent acts of risky sex than others.12 
Nevertheless, inconsistent use and adherence to Truvada is 
associated with developing drug-resistant mutations that can 
be transmitted to others, and can increase HIV infections 
among individuals and within communities, rather than 
decreasing it. Together, these contextual factors place 
African American MSM at high risk for acquiring HIV and 
transmitting it in their communities. 
Overall, interventions have not been successful in 
effectively reducing HIV rates in the African American 
population. A fairly recent FDA-approved strategy for HIV 
prevention is to use Truvada also known as PrEP, as HIV 
pre-exposure chemoprophylaxis. In clinical trials Truvada, 
which is a combination of antiretrovirals—namely tenofovir 
and emtricitabine—in a fixed-dose tablet, showed efficacy 
to protect against HIV infection13, 14 Consequently in July, 
2012 the FDA approved Truvada for daily oral use among 
adult persons at high risk for HIV and who are confirmed to 
be HIV-negative. Truvada, as HIV pre-exposure 
chemoprophylaxis, is an intensive approach that requires 
strict use and adherence.15, 16 Though not a first line of 
defense against HIV, Truvada is recommended as part of a 
comprehensive set of strategies to prevent HIV infections in 
individuals who have high-risk sex and do not use effective 
barrier prevention methods consistently.15, 16  
These guidelines15,16 for the use of Truvada are 
intended to increase efficacy thus mitigating the risk of 
acquiring HIV, and reducing morbidity. The guidelines 
indicate that Truvada has the best efficacy when taken daily 
and with consistent use of condoms from start to end of sex. 
HIV and sexually transmitted infection checks with a 
primary care provider, along with counseling to provide 
support for medication adherence and risk-reduction 
behaviors occurring at least every 3 months is 
recommended. Additionally, Truvada is not recommended 
for coitally-timed and other non-continuous daily use. 
These rigorous guidelines alone can discourage those 
at high risk for HIV from using and adhering to Truvada. 
Yet, adherence to these recommendations is critical to the 
efficacy of the medication regimen to prevent new HIV 
infections. Suboptimal Truvada adherence can produce less 
effectiveness as demonstrated in the iPREX study14 where 
HIV acquisition risk was 21% among participants with less 
than 90% adherence versus 73% among participants with 
greater than 90% adherence. The PARTNERS Truvada 
study also had similar findings.13 Although Truvada holds 
promise as a tool in the arsenal of HIV prevention strategies, 
the potential emergence and spread of drug resistant strains 
resulting from suboptimal adherence can negate the 
benefits17 while inadvertently increasing community HIV 
viral loads.  
Theoretical Framework 
The unique structural violence18 experience in the 
U.S. has been the context in which sexual risk behaviors 
occur particularly for inner city African Americans. Within 
the concept of structural violence ‘structural’ refers to social 
structures, specifically economic, political, legal, religious 
and cultural forces. ‘Violence’ refers to avoidable 
oppression and domination that manifest in social inequities 
and injustices, and cause emotional and even physical 
injury. Structural violence is a chronic affront to human 
wellbeing, harming or killing people slowly through 
relatively permanent social arrangements that are 
normalized and deprive some people of basic need 
satisfaction.19  
Truvada holds promise to reduce HIV acquisition 
particularly for highly at-risk groups. However sex risk 
behaviors of African American MSM occurs within a 
context of structural violence that must be considered. To 
our knowledge no studies have examined Truvada use and 
adherence in post-incarcerated, HIV-negative, African 
American MSM. This population is unique in both its high 
prevalence of HIV—given the three risk factors of being a 
man who has sex with men, African American, and formerly 
incarcerated—and in their experiences of structural 
violence. In this study interpersonal and socio-cultural 
factors that can influence use and adherence to Truvada will 
be examined within the context of structural violence, where 
sex risk behavior occur and within which HIV rates 
continue to proliferate in African American communities.  
Methodology 
Once approval from California State University Los 
Angeles’ Institutional Review Board was secured, the study 
was conducted collaboratively with the Men’s Central Jail 
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in Los Angeles (MCJ) and the Center for Health Justice 
(CHJ), a community-based organization located in close 
proximity to the MCJ. Convenience sampling was used to 
recruit participants from the K6G unit of the MCJ that 
houses gay, bisexual, and transgender persons. Two CHJ 
staff that interacted regularly with inmates in education 
sessions they conducted at the MCJ informed inmates who 
were MSM of the study and gave them a telephone number 
to call a study-related researcher for eligibility screening 
after release from incarceration. Men who called to be 
screened were informed that the purpose of the study was to 
understand the perceptions of taking Truvada, an HIV 
prevention medication, among African American MSM. 
Recruitment also occurred through snowballing techniques 
whereby participants were asked to refer other MSM for 
screening. Before conducting focus groups participants were 
asked to read the consent form, then it was read to them out 
loud. Questions clarifying expectations about their 
participation were answered before they signed the form and 
each participant was given a copy of the consent form.  
A total of 8 focus groups were held (n=47). The 
challenge was in recruiting the desired 6-8 participants for 
each group according to Crabtree and Miller’s (1999)20 
metric for most effective focus group sizes. Participants 
explained that many MSM released from MCJ had 
difficulties financing transportation to the CHJ where focus 
groups were conducted. Often times they did not have 
access to a vehicle or money for public transportation. In 
other instances drug and/or alcohol use or prostitution 
interfered with their ability to keep focus group 
appointments. Nonetheless, data collection was discontinued 
after saturation was reached. Focus groups were held at the 
CHJ in a room that afforded privacy. Participants were told 
that they are free to say what they think and feel using any 
language with which they are comfortable, without 
reservations. They responded by being vocally explicit. 
Participants were encouraged to maintain confidentiality 
about all information revealed in the focus group 
discussions. Each focus group was audio-recorded, and 
lasted one and one-half to two hours. Semi-structured 
questions were used in all focus groups. An iterative process 
was used whereby data from each group informed the 
efficacy of conducting subsequent groups as it pertained to 
understanding how best to communicate effectively with 
participants and interacting comfortably and genuinely with 
them.  
In order to help the men understand how Truvada 
should be used the CDC guidelines were explained. They 
were told that best efficacy with Truvada meant that this 
medication should be taken daily by adults to prevent HIV 
infections as a woman takes birth control pills daily to 
prevent unwanted pregnancies. Consistent use of condoms 
from start to end of sex is also necessary. In addition, 
medical checks every 2-3 months to be certain that there 
was no conversion to HIV-positive status, and checks for 
acquisition of sexually transmitted infection, as well as 
counseling are also necessary. Open-ended questions were 
then asked. Each participant received $40.00 in cash for 
focus group participation. 
Participants 
Participants were self-identified African American 
MSM, were HIV- negative, and recently post-incarceration. 
Ages ranged from 22-58 years with a mean age of 43; 45% 
completed high school; one had earned a master’s degree. 
Most had participated in transactional sex. All were 
unemployed. All used street drugs either currently or in the 
past. All men whether homeless or not resided in the city of 
Los Angeles or West Hollywood where HIV rates were 
46.3% and 18.4% respectively of the percentage of Los 
Angeles County HIV cases in 2009.21  
Analysis 
Focus group data collected from November 2011 to 
July 2012 centered on the following core questions: What 
attitudes do African Americans have about HIV 
medications? What would interfere with using and adhering 
to Truvada? What would interfere with using condoms with 
Truvada? What would cause a man who has been 
incarcerated to take Truvada? Facilitators used probes to 
further clarify participants’ responses. 
Data were professionally transcribed verbatim, all 
identifiers were removed and after multiple readings 
transcribed data were entered into ATLAS.ti, a qualitative 
research computer software package. Three study-related 
researchers independently coded, then met regularly to 
compare the codes and thematic patterns for agreements and 
inconsistencies. A constant comparative method was used 
from the beginning of data collection.  
Findings 
To our knowledge this is the first study to examine 
Truvada use and adherence among post-incarcerated, HIV-
negative, African American MSM. The participants in this 
study are men at high risk for HIV. All men acknowledged 
engaging in high-risk sex. They engaged in receptive and 
insertive condom-less anal sex with multiple partners, 
participated in sex for compensation with drugs, and had sex 
under the influence of various street drugs. Of the 47 MSM, 
two had prior knowledge of Truvada. They had knowledge 
that the medication is known as Truvada or PrEP, and that it 
is used to prevent HIV, however they had no knowledge of 
the guidelines for using this medication. This is similar to 
other reports.22  These authors also reported little increase in 
knowledge of Truvada over time, albeit in a sample that 
included a small number of African American MSM. The 
following five major themes emerged from the current 
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study:  
1. HIV-related stigma continues in African American 
communities. 
2. Post-incarcerated HIV-negative African American 
MSM may not consistently use or adhere to Truvada. 
3. Use of Truvada may be interpreted to mean that 
the user is HIV positive or gay. 
4. African American MSM may not use condoms with 
Truvada. 
5. Truvada should be given to men who are 
incarcerated.  
 
HIV-related Stigma Continues in African American 
Communities 
 
 The participants in this study indicated that in 
African American communities, and particularly among gay 
African American men, there is still difficulty talking about 
HIV and HIV-related matters including HIV medications. 
One man stated with agreement from the other participants, 
“HIV is still a sensitive subjective.” Another said, “African 
Americans have a hard time saying ‘HIV,’ and talking about 
anything related to it.” Another said, “HIV and HIV 
medications are not discussed.” Another participant’s 
statement related to a generalized perception of lack of 
acceptability of gay African Americans that might 
contribute to social marginalization and HIV stigma: “To be 
considered part of the, I don’t even know the initials, gay 
and lesbian and transgender community you have to be 
White. It is acceptable in White communities. Otherwise you 
are just a punk.” This finding that HIV stigma is still 
problematic in African American communities is similar to 
other reports.23 These researchers also found a higher level 
of stigma among persons taking antiretroviral medication, 
and that stigma can be related to high-risk sexual behaviors. 
Others have reported a positive correlation between HIV 
stigma and depression, low social support, low self-esteem, 
and loneliness, indicating that the experience of stigma can 
cause psychological effects.24 Difficulty talking about HIV 
may help explain the association between lack of partner 
disclosure of HIV status and increased sexual risk-taking 
behaviors.25 In that study, African Americans who were able 
to disclose their HIV status were less likely to engage in 
unsafe sex. The CDC (2011)26 has also indicated that stigma 
is related to HIV health behaviors.  
 
 Although HIV prevention strategies including 
increased awareness, testing, and condom use help to reduce 
HIV transmission and acquisition, HIV stigma can 
undermine these efforts since an inability to talk about HIV 
related matters directly affects the ability to garner support 
for safe sex behaviors from partners. Yet there are few 
culturally based interventions to reduce HIV stigma in 
African American communities. The finding that HIV-
related stigma continues in African American communities 
indicates that there is still a need for interventions to help 
reduce HIV stigma. Culturally tailored interventions for 
African Americans to encourage freer discussions with their 
family, friends, and sexual partners and may help increase 
safe sex behaviors, thereby potentially reducing HIV 
infection rates.  
 
 
Post-Incarcerated, HIV-Negative, African American 
MSM May Not Consistently Use or Adhere to Truvada 
 
 Not using and adhering to Truvada according to the 
CDC guidelines can cause HIV acquisition and 
transmission21 however more than 75% (35 of 47) of the 
men in this study indicated that they would not use or 
adhere to Truvada. The task of having to take Truvada daily 
was seen as problematic by most men, reflecting HIV 
medication use and adherence problems that are already 
prevalent among African Americans.27 As stated earlier, 
these men used street drugs either currently or in the past, 
and the use of street drugs can alter judgment and behavior 
such that persons who use street drugs may not adhere to 
HIV medications,28 therefore adherence to Truvada could be 
problematic for some groups. Using and adhering to 
Truvada was an area of extensive discussion among the 
participants who gave several reasons why they may not use 
and adhere to Truvada. One participant indicated, as others 
agreed: 
 “Black men, African American men we all don’t. It’s 
already statistically shown that we do not go to the doctors, 
we do not take medications. Just like with stuff like  
diabetes and other kind of illnesses we don’t even take meds 
for that. I don’t see us doing the HIV pill. That’s asking a 
lot, you know what I mean?” 
 Another explained, “Because we are already 
suffering high blood pressure. That’s just another pill.” 
  Another explained, “I think the youth. That’s the one 
we should focus on because they are having sex anywhere, 
any place, anytime.” 
 Another explained, “Three fourths of Black men that 
have sex with men are not going to do so. They’re not going 
to take a pill everyday.” 
 Another added, “The only thing is taking it 
everyday.” 
 Another questioned, “Do you take it in the morning, 
afternoon or dinner? It’s just another job you gotta do.”  
 One participant explained, “See most people who 
need that drink and smoke… That’s why I am saying I 
wouldn’t take it because when I’m not in the recovery mode 
I drink and I smoke, and I’m not talking about smoking 
weed. I’m talking about hard stuff, you understand me? I 
want to know if it would be effective if I was smoking crack 
or something like that? Have you guys went out to crack 
heads, people smoking meth to see if it was effective?” 
 Another agreed, “Like my man here was saying, 
there are other little medications, your personal stuff. A lot 
of people see psychiatrists for psych, you know. If you mix 
those pills together and they don’t connect…” 
 Another questioned, “Can you take it with alcohol?” 
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 Another added, “If I am taking this I plan to catch it 
[HIV].”  
 Another participant questioned, “What happens if 
you’ve been taking this medication all this time then all of a 
sudden you somehow catch HIV, then you are resistant to 
what you’ve been taking? And then what’s gonna help 
you?” 
 One participant stated and others agreed about beliefs 
in an HIV conspiracy theory that would prevent them from 
using and adhering to Truvada:“I mean if it is something 
that is actually beneficial where contracting AIDS is 
concerned, or not contracting it then it’s a great idea. But 
the thing about it is that a lot of us, we as people feel like it 
was like HIV and AIDS was formulated somewhere and the 
government had a big hand in it or whatever. And I mean I 
would be afraid to take anything that had anything to do 
with HIV and AIDS.”  
 Another added, “The bible said that the government 
is corrupt anyway.” 
  For the aforementioned reasons another participant 
concluded, “I ain’t taking that shit.” 
 Participants offered several other reasons for not 
using and adhering to Truvada. One participant stated and 
others affirmed, “…the side effects that one person might 
get, how you know your body can handle that? Everybody 
body not the same so then my head is like why would you 
take this medicine?” Some participants had concerns that a 
proper diet may be necessary with Truvada. One participant 
stated, “You have to eat right to take HIV medication. If 
you’re on the streets and you are taking HIV medication 
[Truvada] and you are not eating right that could be a 
problem.” 
 One participant who may consider using Truvada 
stated, “I think I would. Only if it came in the same package 
with condoms.”  
 One of the participants offered an explanation of its 
usefulness to persons engaged in transactional sex with 
affirmative nods from the other participants: “I think it 
would be really, really good like for a sex worker. 
Somebody who is a sex worker and they do that on a daily 
basis because that way every time they bust open that 
condom they will be able to take their pill for that day. They 
will be more likely to say, okay, I’m a hoe, but I am going to 
go ahead and take this pill and use this condom in case I 
slip up or the person slip up, I’ve still got a little barrier.” 
 Another participant offered an explanation for when 
a man should use Truvada: “Now, if a man was messing 
around with somebody else, he should use it if he was 
messing around with somebody else, he should use condoms 
and still take the pill, but if it was just you and your 
partner...” 
 Men were also concerned about the cost of Truvada. 
“Who is gonna pay for this if you want to take this 
medicine? Who’s gonna pay for it? If they’re trying to help 
us to prevent it in the African American environment why 
should we have to pay for it because they know our 
circumstances. You know most Blacks, African Americans, 
we are on low-income, Section 8. But why would you put it 
out there to help us if our income and our capability, how 
would we pay for it? I don’t even know if I would do it if it 
was free so having to pay for it at all?” 
 
 
 Finally one man explained, “Hell, I smoke weed and 
I drink and get high so I’m going to die from something. So 
it might as well be from that shit [HIV/AIDS].” 
 
 The many reasons offered here help explain why the 
men in this sample would not be likely to use and adhere to 
Truvada. This finding is in contrast to other reports that 
most African American MSM would use Truvada.22,29 This 
incongruence may be explained by the dissimilarities 
between the samples. The samples in these studies had a 
higher socio-economic and educational status than the men 
in the current study, and were not recently post-incarcerated. 
In addition each of these studies had small African 
American samples.  
 
Use of Truvada May Be Interpreted to Mean That the 
User Is HIV Positive or Gay. 
 
 Sexual risk behaviors can be influenced in person-
person relationships where they occur, and on sociocultural 
levels as well. These interpersonal influences could cause a 
person to not use and adhere to Truvada. Participants 
indicated that the possible misperception by a partner—that 
taking medication to prevent HIV would mean the 
individual had HIV—was one factor that could interfere 
with using and adhering to Truvada.  
 One man said “I think it is going to be hard to take 
this medication because the reason why I think it’s going to 
be hard because then the other person will think you have 
HIV even though you don’t.”  
 Another offered, “The other person will think you are 
positive and you’re not and he’s going to say why are you 
taking this medication.”  
 Another offered, “Why you taking this medication? 
Even though you’re going to be honest and to say to that 
person I’m not positive. Well, why you have this medication. 
And you are going to have a big old argument right there.” 
 On a socio-cultural level, participants indicated other 
forms of assumptions friends and family may have about 
taking Truvada: the judgment, isolation, secrecy and 
potential threats to relationships that could occur although 
the medication is being used as HIV chemoprophylaxis.  
 One participant stated, “People might think you 
gonna get a pill so you can mess with them boys.”  
 Another stated, “I don’t think people would like 
people knowing what you’re taking because they have so 
many thoughts about what is he doing, why is he taking this, 
what is that.”  
 Another offered, “Is he gay or is he not gay. What I 
mean, why is this guy taking this. That you might be ill 
[have HIV infection]. You know they wouldn’t want to drink 
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after you, smoke, anything after you. They might not even 
want to talk to you.”  
 In agreement another participant stated, “Exactly  
what he said is people looking at you taking certain 
medicine, even though it is Truvada it’s still HIV medication 
you are taking.”  
 Another participant talked about perceived 
interpersonal and socio-cultural challenges to taking 
Truvada saying, “That would be another stumbling block 
for me. People asking me what the hell are these? You got 
something? Something wrong with you?” 
 Another echoed similar opinions, “If somebody see 
you taking them, they go, what are you taking, you got 
AIDS. If you taking this pill everyday this means something 
is wrong with you. This means you’ve got to try to hide it or 
you know, just keep it away from people.”  
 Another participant stated, “So a person sees you 
takin’ the same pills as an HIV person they automatically 
thing you got HIV no matter what you tell ‘em. They are not 
going to have sex with you because they are going to be too 
afraid that you actually have HIV, and you are just lying to 
them.”  
 The importance of the finding that someone taking 
Truvada may be assumed to be HIV-positive or gay could 
interfere with a person using and adhering to this 
medication, which is meant to prevent HIV acquisition and 
transmission. The statements by participants underscore 
how both interpersonal interactions and socio-cultural 
influences can impact health behavior. These statements 
also underline a lack of knowledge about Truvada among 
the participants. The implication here is that including 
Truvada education at both individual and community levels, 
when designing interventions for the HIV/AIDS public 
health crisis in African American U.S. communities, may be 
helpful. 
 
African American MSM May Not Use Condoms with 
Truvada 
 
 Condom use alone has long been known as an 
efficacious means of reducing the risk of acquiring HIV. As 
indicated earlier, efficacy to prevent HIV with Truvada 
requires strict adherence to the CDC guidelines, which 
include not only using Truvada daily, but using condoms 
from start to finish of each sex act21 Additionally, Truvada 
could be useful for persons who do not use condoms 
consistently. Whether persons using Truvada would also use 
condoms at each sex act has been an important question 
among researchers. Not using condoms with Truvada, which 
has been referred to as “risk compensation,” “behavioral 
dis-inhibition,” or “condom migration” is concerning since 
this behavior could offset the preventive benefits of 
Truvada, thus increasing HIV rates instead of decreasing 
it.30,31 However, participants questioned the logic of using 
condoms along with using Truvada, and rationalized how 
inconsistent use of Truvada and condoms could occur. 
 One participant questioned, “Why not just use 
condoms, what is the point?” 
 Another also questioned, “Why would I have sex and 
have to use medication and condoms anyway? I’m using 
condoms now, I’m going to take medication and I have to 
use a condom to have sex. That just don’t make sense.” 
 
 Another agreed, “Thank you because I was trying to 
understand that because if I’m taking the medication to not 
get HIV that should be all there is if I’m not going to get 
HIV.” 
 Another added, “I have been trying to find a way 
around condoms, so if I have Truvada I may not use 
condoms.” 
 Another explained, “Only if somebody is getting to 
know me, only if I’m going to be involved with this person in 
a relationship I wouldn’t use it, but if it is a booty call or 
something I’ll just take my pill and just use my condoms.”  
 Another explained hypothetically how some may 
engage in sex risk behaviors that could put them at risk by 
not using condoms consistently when they are taking 
Truvada: “It’s gonna be like, oh man I got this pill, I’m 
good. I don’t got to use no condom, you know. People will 
just be like going out there having sex because they got the 
pill.” 
 Another explained, “Because they’re going to say, 
why am I using a condom, or they’re going to say, why am I 
taking the pill when I have the condom.” 
 Another explained, “It will be like fuck the condom. 
I’m not going to use a condom, I’m just going to take this 
pill and go out and pound something because I’ve got the 
pill. They say it is going to protect me.” 
 
 The finding that African American MSM may not 
use and adhere to condoms with Truvada is similar to other 
reports. Brooks et al. (2012)32 found that 64% of 
participants in their study indicated a likelihood of engaging 
in sexual risk behaviors, and 60% indicated a likelihood of 
non-condom use with HIV pre-exposure chemoprophylaxis. 
Although the men in the current study were at high risk for 
HIV acquisition most did not seem to see the benefit of 
adding Truvada to a sexual routine that may already have 
included using condoms that have known efficacy. 
Additionally, the findings suggest that intimacy may play a 
part in condom use since partners may question its use with 
Truvada.33 However, participants’ comments imply that 
condom use with Truvada may depend on the type of 
interpersonal relationship a person may have with another 
person.29  
 
Truvada should be given to men who are incarcerated. 
 
Sex among male inmates occurs and between 20% and 26% 
of people living with HIV/AIDS in the United States have 
spent time in the correctional system.34 This positive 
association between HIV and incarceration35 coupled with 
higher incarceration rates for African Americans (4,777 per 
100,000) as compared to White males (727 per 100,000) 
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increase HIV risk more so among African Americans.36 In 
addition, it has been reported that 51% of incarcerated men 
engage in unprotected sex on the first day of release and 
81% by the first week.37 At the K6G unit of the MCJ where 
the sample for this study was recruited, there have been 
reports of oral and anal sex among male inmates.38 In 
response to Truvada use and adherence among incarcerated 
MSM, participants indicated that HIV chemoprophylaxis 
should be provided to them because men have sex with each 
other while incarcerated.  
 One man began by describing how sex between 
incarcerated men can occur: 
“You push two bunk beds together and you have two  
[sheet]covers hanging over so can’t nobody see. So it’s like 
a queen sized bed on the bottom. You hang your sheets so 
it’s like you’re enclosed…” 
Others concurred with one man’s statement that 
“There’s a lot of sexual activity that goes on in there.” 
 Another added, “And they ain’t using condoms.” 
 Another added, “They [incarcerated MSM] should 
have it [Truvada] because I’ve known some people that 
went in jail and came out positive...” 
 Another concurred, “My uncle went to prison and 
when he came out he had HIV.” 
 While men felt incarcerated MSM should have 
Truvada, using and adhering to this medication was seen as 
problematic. Condom use with Truvada again surfaced as a 
problem since condom use with Truvada is necessary 
however access to condoms while incarcerated is 
problematic, making it difficult to adhere to CDC guidelines 
for Truvada. Also, the same concern mentioned earlier, that 
partners could question Truvada use surfaced again.  
 One man stated as others concurred, “They 
[partners] will think you’re sleeping around.” 
 Another explained the difficulty in using Truvada if 
you are re-connecting with a partner upon release from 
incarceration, and gave an anticipated partner’s response: 
“You will have to hide it. You’re hiding it because you’ve 
been in jail or prison and if you only been messin’ with me 
and I haven’t messed with anybody since you’ve been gone, 




     Findings in this study help the understanding of 
factors that may influence use and adherence to Truvada in 
a subgroup of African American people that are highly at 
risk for acquiring and transmitting HIV, that is, post-
incarcerated, African American MSM. Implied in the 
findings, and also indicated in other findings, is that sex risk 
behaviors can be influenced on interpersonal as well as on 
sociocultural levels.39,33 However, African American sex 
risk behaviors occur within a unique history of longstanding 
structural violence, yet these behaviors are often examined 
in isolation and without this context. The men in this study 
could only respond to Truvada use and adherence in the 
context of structural violence in which they exist, having 
poverty of material and informational wealth, limited trust 
in the health care system caused by a history of unethical 
treatment in research, and limited access to the health care 
system. Poor treatment in the health care system driven by 
racism and homophobia is compounded for African 
American MSM. A deeper impact is meted out to those who 
have a history of incarceration and must manage racism and 
homophobia along with post-incarceration 
disenfranchisement that ensures recidivism and a likelihood 
of permanent location on the fringes of American society.  
 
 While the findings in this study have significance for 
use and adherence to Truvada, which can be helpful in 
reducing HIV acquisition and transmission in post-
incarcerated, African American MSM, these contextual 
factors function to interfere with use and adherence to HIV 
chemoprophylaxis. The majority of these men had no 
information about Truvada. Reasons given for not being 
likely to use and adhere to Truvada included the 
inconvenience of taking it daily, and the lack of logic for 
using condoms with Truvada when condoms have known 
efficacy to prevent HIV when used properly and 
consistently. They also indicated that drug use and passion 
could deter condom use with Truvada. However, limited 
access to Truvada due to unmanageable cost also surfaced 
as a reason participants may not use and adhere to the 
medication, as did a lack of trust in the health care system, 
causing the participants to consider Truvada as a conspiracy 
to intentionally infect them with HIV given past 
transgressions in U. S. research exemplified in the Tuskegee 
Syphilis study.  
 
 The finding of continued stigma and the implication 
that there is still a lack of HIV-related discussions could 
prohibit disclosure of HIV status, hence the continued need 
for HIV education. Health literacy is the degree to which 
individuals have the capacity to obtain, process, and 
understand basic health information. 40 This is necessary in 
order to make effective health care decisions for oneself. In 
as much as Truvada can be useful in persons with similar 
characteristics as participants in this study sample, health 
illiteracy as it regards Truvada—being uninformed about 
this medication, and lacking the capacity to access and use it 
according to the guidelines—can prohibit the actualization 
of any benefit this drug can offer as a prevention option for 
HIV. The finding that Truvada use may be interpreted to 
mean the user is HIV positive or gay, as well as the finding 
that participants may not use condoms with Truvada if they 
had access to this medication also signal the need for 
education regarding Truvada. This education must be 
culturally tailored to the needs of specific high-risk groups 
in order for it [HIV chemoprophylaxis] to be used and 
adhered to as intended. The preponderance of HIV 
infections among African American MSM calls for an 
urgent focus on those that are at high risk, particularly 
subgroups such as African American MSM with a history of 
incarceration. 
 
©The Author(s) 2016. This article is published with open access by the GSTF.
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